Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology and Hepatology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Women’s Health Knowledge Hub Advances in Alzheimer’s

Navigating neuroimaging in Alzheimer disease care

PET imaging is playing an increasingly critical role in managing AD, but how can you effectively integrate it into clinical practice? Our expert-led program will empower you with practical strategies and real-world case studies.

This content is intended for healthcare professionals outside of the UK.
ADVANCED SEARCH
Log in
Internal Medicine Rheumatology

Rheumatology

IL-17A inhibition in rheumatic and musculoskeletal diseases

Targeting the IL-17 pathway has already transformed the management of psoriatic arthritis and axial spondyloarthritis, and now IL-17A inhibitors are being explored in giant cell arteritis and polymyalgia rheumatica.

Read more

Editor's Choice

Novel association of chilblains with inflammatory arthritis

  • Free for a limited time
  • Arthritis
  • Case Study

Three patients with inflammatory arthritis had concomitant chilblains and bone marrow edema as revealed by MRI. Could this trifecta represent a new clinical phenotype of seronegative spondyloarthropathies?

Study supports first-line biologics for Still disease

Frontline use of biologic versus conventional synthetic DMARDs for adult-onset Still disease is associated with higher rates of sustained event-free remission.

AI to predict treatment response in RA and SpA

Artificial intelligence technologies show substantial potential in predicting treatment responses in rheumatoid arthritis and spondyloarthritis. However, challenges such as methodological variability, data integration, and external validation remain.

Disease-modifying therapies in lupus nephritis

Of the current treatments for lupus nephritis, how many can be classed as disease modifying according to recently proposed criteria? And what are the challenges and considerations for future studies?

Our tailored content service will keep you up to date…

Receive newsletters curated for the busy specialist by our expert editorial team

Register today

Episode 17: Challenges of developing DMOADs

Why are disease-modifying treatments for osteoarthritis such a difficult proposition?

Despite multiple attempts, no DMOAD is yet approved for clinical use. Prof. Ali Mobasheri takes us through the main challenges, the work being done to make these so-called utopia drugs a reality, and discusses other advances that offer hope in the meantime.

Prof. Ali Mobasheri
Listen now
Podcast

Latest News

Study supports first-line biologics for Still disease

Upadacitinib may offer a glucocorticoid-sparing option for GCA

Reduced infection risk with IL-targeting biologics

Pros and cons of glucocorticoid cessation

Caution urged over interpreting MRI-detected erosion

Ixekizumab slows bone damage in axial spondyloarthritis

Case Studies

Novel association of chilblains with inflammatory arthritis

  • Free for a limited time
  • Arthritis
  • Case Study

Three patients with inflammatory arthritis had concomitant chilblains and bone marrow edema as revealed by MRI. Could this trifecta represent a new clinical phenotype of seronegative spondyloarthropathies?

Early atypical MRI findings in Neuro-Behçet's disease

In pediatric patients with unexplained neurological symptoms and MRI findings of lateral ventricular lesions or brainstem-thalamus-basal ganglia abnormalities, monitor closely for BD signs.

SLE presenting with bilateral retinal vasculitis

A unique case of bilateral retinal vasculitis as the initial manifestation of systemic lupus erythematosus. Recognizing the possibility of such atypical presentations allows clinicians to maintain a high index of suspicion for SLE.

Keynote webinar | Spotlight on advances in lupus

  • Live
  • Webinar | 27-05-2025 | 18:00 (CEST)

Systemic lupus erythematosus is a severe autoimmune disease that can cause damage to almost every system of the body. Join this session to learn more about novel biomarkers for diagnosis and monitoring and familiarise yourself with current and emerging targeted therapies.

Join us live: Tuesday 27th May, 18:00-19:15 (CEST)

Prof. Edward Vital
Prof. Ronald F. van Vollenhoven
Developed by: Springer Medicine
Register now
Webinar

Current Reviews

Emerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a monogenic autoinflammatory disorder with significant morbidity and mortality. Numerous treatment options including azacitidine, JAK inhibitors, IL-6 inhibitors …

CAR-T cell therapy in rheumatic diseases: a review article

CAR-T cell therapy, a pioneering immune-modulating treatment that was initially designed for hematologic malignancies, is now being considered a potential treatment for autoimmune and rheumatic diseases. This method involves genetically …

Linking Hyperuricemia to Cancer: Emerging Evidence on Risk and Progression

Metabolic diseases posed a significant global burden in 2021, with reported cases including 226 million individuals with hypertension, 129 million with obesity, 88 million with hypercholesterolemia, 75 million with type 2 diabetes mellitus (T2DM) …

Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians

Ten adalimumab biosimilars have been introduced in the United States (USA) since 2023, while adalimumab biosimilars have been available for several years in other countries. These experiences of biosimilar uptake outside the USA can inform …

Elevate your expertise in aplastic anemia (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME
Learn more

CME & eLearning

eLearning (Link opens in a new window)

Transform the way you care for your patients with aplastic anemia with our 3-module series using real-world case studies and expert insights. Discover why early diagnosis matters, explore the benefits and risks of current treatments, and develop tailored approaches for complex cases. 

Supported by:
  • Pfizer
Developed by: Springer Healthcare IME

Further Reading

Emerging treatment approaches for VEXAS syndrome: a systematic review and meta-analysis

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is a monogenic autoinflammatory disorder with significant morbidity and mortality. Numerous treatment options including azacitidine, JAK inhibitors, IL-6 inhibitors …

Prevalence and incidence of osteoporotic vertebral fractures in community-dwelling European older adults: an observational analysis of the DO-HEALTH trial

Vertebral fractures (VFs) are the most common type of osteoporotic fractures [ 1 – 3 ]. Once a VF is sustained, the risk of subsequent fractures increases significantly, particularly in the first two years after the fracture: 40 to 60% of all …

Evaluation of autoimmune and inflammatory markers in bilateral sudden hearing loss

Sudden Hearing Loss (SHL) is a sensorineural hearing loss that develops within 72 h, resulting in a loss greater than 30 dB across at least three consecutive frequencies [ 1 ]. SHL is considered an otologic emergency, with an incidence of 5–20 per …

Patient-Reported Outcome Measures in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis Treated with GP2015, an Etanercept Biosimilar: Results from Two Phase III Studies (EGALITY and EQUIRA)

Rheumatoid arthritis (RA), psoriasis (PsO), and psoriatic arthritis (PsA) are chronic inflammatory immune-mediated diseases associated with significantly impaired quality of life (QoL) [ 1 – 3 ]. The introduction of targeted (biologics) therapy …

Related topics

Lumbar sympathetic block to treat CRPS in a toddler

After non-invasive measures failed, a lumbar sympathetic block performed with extreme caution alleviated complex regional pain syndrome in this 18-month-old.

Read more

Self-guided digital behavioral therapy for fibromyalgia

Caution needed when prescribing gabapentinoids in people with COPD

Illness uncertainty in hypermobile Ehlers-Danlos syndrome

Neurostimulation therapies for chronic pain

IL-17A inhibition in rheumatic and musculoskeletal diseases

Targeting the IL-17 pathway has already transformed the management of psoriatic arthritis and axial spondyloarthritis, and now IL-17A inhibitors are being explored in giant cell arteritis and polymyalgia rheumatica.

Read more

Novel association of chilblains with inflammatory arthritis

  • Free for a limited time
  • Arthritis
  • Case Study

Study supports first-line biologics for Still disease

AI to predict treatment response in RA and SpA

Disease-modifying therapies in lupus nephritis

Upadacitinib may offer a glucocorticoid-sparing option for GCA

Osteoporosis and osteoarthritis in elderly patients

What are the key considerations for managing osteoporosis and osteoarthritis in the oldest old (≥80 years), in the context of multimorbidity, physical and mental disability, and polypharmacy?

Read more

Biomarkers in hand osteoarthritis

Use of platelet-rich plasma in rheumatic diseases

Are heated mittens useful in osteoarthritis?

Better pain relief with total hip replacement for hip osteoarthritis

Semaglutide shows promise for obesity-related osteoarthritis

ALS in a patient with CLL and drug-related SLR

A man with a skin rash and left leg weakness was diagnosed with sarcoid-like reaction due to treatment for chronic lymphocytic leukemia, and ultimately also amyotrophic lateral sclerosis when the motor symptoms progressed.

Read more

Cardio-rheumatology: an emerging specialty

Corticosteroids for hydrocephalus in neurosarcoidosis

Complications from conduction system pacing

Concurrent sarcoidosis and hypersensitivity pneumonitis

Current applications of AI in sarcoidosis

Image Credits